Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Names University of Liverpool’s CGR as Certified Service Provider

Published: Monday, July 23, 2012
Last Updated: Monday, July 23, 2012
Bookmark and Share
CGR achieves certified status for Agilent SureSelect target enrichment system for next-generation sequencing.

Agilent Technologies Inc. has announced that the University of Liverpool’s Centre for Genomic Research has become the UK’s first Certified Service Provider for the Agilent SureSelect Target Enrichment System for next-generation sequencing.

The CGR has been conducting research at the leading edge of genomic technologies and data analysis in Liverpool, England, for over a decade.

With a diverse portfolio of projects including metagenomics, plant and animal studies, cancer genomics and human genetics, the CGR is constantly exploring new technologies and making innovative approaches and applications available to researchers investigating fundamental and applied biology.

SureSelect has been shown to greatly increase the speed and efficiency of next- generation sequencing by enabling researchers to focus experiments on genomic regions of interest rather than sequencing the entire genome.

Since it was introduced in 2009, SureSelect has been instrumental in more than 250 published studies covering research into a wide range of heritable disorders and complex diseases.

“We have relied on SureSelect in our research efforts to produce consistent results that we and our collaborators can be confident in,” said professor Andy Cossins, head of the Institute of Integrative Biology and co-director of the Centre for Genomic Research. “Achieving certified status is an important step for the CGR and will allow us to expand our sequencing leadership.”

“The CGR is a highly regarded collaborator in the sequencing community, and we're pleased that they are now enabling more researchers across the UK to access the market-leading platform for target enrichment,” said Kathleen Shelton, senior director of Genomics Marketing at Agilent.

Shelton continued, “Their certification is a great complement for our SureSelect portfolio and will be a great benefit to collaborators.”

To be certified, the CGR participated in comprehensive on-site training and then passed a rigorous set of requirements to demonstrate expertise and skill.

The SureSelect portfolio now includes more than 21 products, and many more are in development. SureSelect is compatible with major sequencing platforms such as Illumina, SOLiD and 454.

Users of Agilent’s eArray design tool can improve the efficiency of their research by easily designing custom products to target any genomic regions of interest. SureSelect also allows customization of catalog kits with the addition of custom content.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Awards Influential Clinical Genomics Researcher
Dr. Peter Robinson recognized for contributions to clinical genomics and computational biology.
Tuesday, November 29, 2016
Influential Cancer Researcher Receives Agilent Thought Leader Award
Biologist Scott Lowe receives award in recognition for his contributions to cancer biology.
Thursday, October 27, 2016
Agilent’s Non-Small Cell Lung Cancer Companion Dx Receives Expanded FDA Approval
Agilent’s Dako PD-L1 IHC 22C3 pharmDx has an expanded label approved by the U.S. FDA for use in determining PD-L1 expression status to inform treatment in metastatic non-small cell lung cancer with KEYTRUDA® (pembrolizumab).
Tuesday, October 25, 2016
Agilent Technologies to Build New Facility in Colorado
Agilent buys 20 acres in Weld County to increase pharmaceutical manufacturing capacity.
Wednesday, August 10, 2016
Agilent, Eurofins Genomics Collaborate
Agilent plans to offer custom components and an assembled plasmid service for Agilent’s SureVector next-generation cloning kits through a collaboration with Eurofins.
Monday, March 14, 2016
Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics
Company has announced a program that gives biologists conducting functional genomics research early access to a potential new resource.
Saturday, February 13, 2016
Agilent Technologies and 10x Genomics Announce Collaboration
Company has announced collaboration to develop a premium exome that provides a streamlined workflow for 10x Genomics'Chromium platform.
Friday, February 12, 2016
Agilent Extends Agreement with PerkinElmer on Bioanalyzer Chips
PerkinElmer supplies chips for Agilent's popular 2100 Bioanalyzer system.
Thursday, January 21, 2016
Agilent Recognizes Australian Genome Research Facility as Certified Service Provider
Nonprofit organization offers scientists access to leading-edge technologies.
Saturday, October 31, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Announces Global Distribution Agreement with Cartagenia for CNV Analysis
To assist cytogenetic labs in the clinical interpretation of microarray data.
Friday, May 30, 2014
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Gene Editing Yields Tomatoes That Ripen Weeks Earlier
Research team develop method to make tomato plants flower and ripen fruit two weeks faster than current growth rates.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Unexpected Role for Epigenetic Enzymes in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!